Glioma Glioblastoma Multiforme Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 200

To learn more about this report, request a free sample copy

Glioma Glioblastoma Multiforme Market Overview

An overview of conceptual frameworks, analytical approaches of the glioma glioblastoma multiforme market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Glioma glioblastoma multiforme market is expected to grow at a significant rate in the near future and the temozolomide drug type segment is expected to dominate the market over the forecasting period.

The global glioma glioblastoma multiforme market in 2020 is estimated for more than US$ 840.7 Mn and expected to reach a value of US$ 1,504.8 Mn by 2028 with a significant CAGR of 7.6%.

MMC Overview

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that gives a better opportunity for the customers to put their effort.

Glioma Glioblastoma Multiforme Market Dynamics

The studies in the cancer segment is increasingly emphasized and prioritized as a research framework to deal with complex socio-environmental problems this in turn will be used as the data extraction point for the study of the glioma glioblastoma multiforme market. Glioma glioblastoma multiforme is a grade four histological malignancy that forms a central nervous system tumor. According to the World Health Organization, multistep oncogenesis is the main reason behind the 90% of diagnosed glioblastomas multiforme, which are primary gliomas and the 10% remaining are due to low-grade tumors. Glioblastoma is a spontaneously occurring neoplasm. Treatment modalities and prophylaxis depend on the tumor localization, the intensity of its malignancy, genomic profile, and age of the patient, and the score for the Karnofsky performance scale.

In 2018, according to the NCBI, glioblastoma is the most general and frequent type of brain tumor and leads to 225,000 deaths per year around the globe, which represents 30% of the total central nervous system tumors, 45% of malignant CNST, and 80% of primary malignant CNST. The incidence rate of the population suffering from this condition 5 out of 100,000 people, and influence 1.5 times to men in comparison to women, and the average of diagnosis this condition is stated around 64 years

Glioma Glioblastoma Multiforme Market Segmentation

The global glioma glioblastoma multiforme market is segmented on the basis of therapy, treatment type, drug type, and by region.

glioma glioblastoma multiforme market sample

Glioma Glioblastoma Multiforme Market Geographical Overview

In 2012, a study done by the Central Brain Tumor Registry of the United States, glioblastoma is one of the most general and highly invasive malignant brain neoplasms with an incidence of 2–3 new cases per 100,000 people per year around the globe.

Overall Incidence of Primary Brain and CNS Tumour is 22.6/100,000 Population

glioma glioblastoma multiforme market pie chart

Source: CBTRUS, MMC 2019

Glioma Glioblastoma Multiforme Market Competitive Landscape

Some of the key participating players in the global glioma glioblastoma multiforme market are Bristol-Myers Squibb, Genentech, Inc., Emcure Pharmaceuticals Limited, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries, Sigma-Tau Pharmaceuticals, Inc., Sandoz, and Others.

Regional Segmentation

On the basis of region, the glioma glioblastoma multiforme market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa


To learn more about this report, request a free sample copy


1.    Global Glioma Glioblastoma Multiforme Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Glioma Glioblastoma Multiforme Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Glioma Glioblastoma Multiforme Market Snapshot

2.4.    Global Glioma Glioblastoma Multiforme Market Size and Forecast, 2019–2027

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2019–2027)

2.5.    Global Glioma Glioblastoma Multiforme Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Pipeline Study

2.8.    Porter’s Five Forces Model

3.    Global Glioma Glioblastoma Multiforme Market, By Therapy

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Therapy

3.1.2.    BPS Analysis, By Therapy

3.2.    Market Revenue (US$Mn) Forecast, By Therapy

3.2.1.    Segment A

3.2.2.    Segment B

3.2.3.    Segment C

3.2.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

3.3     Global Glioma Glioblastoma Multiforme Market Attractiveness Index, By Therapy

4.    Global Glioma Glioblastoma Multiforme Market, By Treatment Type

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Treatment Type

4.1.2.    BPS Analysis, By Treatment Type

4.2.    Market Revenue (US$Mn) Forecast, By Treatment Type

4.2.1.    Segment A

4.2.2.    Segment B

4.2.3.    Segment C

4.2.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

4.3.    Global Glioma Glioblastoma Multiforme Market Attractiveness Index, By Treatment Type

5.    Global Glioma Glioblastoma Multiforme Market, By Drug Type

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Drug Type

5.1.2.    BPS Analysis, By Drug Type

5.2.    Market Revenue (US$Mn) Forecast, By Drug Type

5.2.1.    Segment A

5.2.2.    Segment B

5.2.3.    Segment C

5.2.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

5.3.    Global Glioma Glioblastoma Multiforme Market Attractiveness Index, By Drug Type

6.    Global Glioma Glioblastoma Multiforme Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Glioma Glioblastoma Multiforme Market Attractiveness Index, By Region

7.    North America Glioma Glioblastoma Multiforme Market Analysis and Forecast, 2019–2027

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Glioma Glioblastoma Multiforme Market

7.2.2.    Canada Glioma Glioblastoma Multiforme Market

7.3.    North America Glioma Glioblastoma Multiforme Market, By Therapy

7.3.1.    Segment A

7.3.2.    Segment B

7.3.3.    Segment C

7.3.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

7.4.    North America Glioma Glioblastoma Multiforme Market, By Treatment Type

7.4.1.    Segment A

7.4.2.    Segment B

7.4.3.    Segment C

7.4.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

7.5.    North America Glioma Glioblastoma Multiforme Market, By Drug Type

7.5.1.    Segment A

7.5.2.    Segment B

7.5.3.    Segment C

7.5.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

7.6.    North America Glioma Glioblastoma Multiforme Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By Therapy

7.6.3.    By Treatment Type

7.6.4.    By Drug Type

8.    Latin America Glioma Glioblastoma Multiforme Market Analysis and Forecast, 2019–2027

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Glioma Glioblastoma Multiforme Market

8.2.2.    Mexico Glioma Glioblastoma Multiforme Market

8.2.3.    Argentina Glioma Glioblastoma Multiforme Market

8.2.4.    Rest of Latin America Glioma Glioblastoma Multiforme Market

8.3.    Latin America Glioma Glioblastoma Multiforme Market, By Therapy

8.3.1.    Segment A

8.3.2.    Segment B

8.3.3.    Segment C

8.3.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

8.4.    Latin America Glioma Glioblastoma Multiforme Market, By Treatment Type

8.4.1.    Segment A

8.4.2.    Segment B

8.4.3.    Segment C

8.4.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

8.5.    Latin America Glioma Glioblastoma Multiforme Market, By Drug Type

8.5.1.    Segment A

8.5.2.    Segment B

8.5.3.    Segment C

8.5.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

8.6.    Latin America Glioma Glioblastoma Multiforme Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Therapy

8.6.3.    By Treatment Type

8.6.4.    By Drug Type

9.    Europe Glioma Glioblastoma Multiforme Market Analysis and Forecast, 2019–2027

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Glioma Glioblastoma Multiforme Market

9.2.2.    Germany Glioma Glioblastoma Multiforme Market

9.2.3.    Italy Glioma Glioblastoma Multiforme Market

9.2.4.    France Glioma Glioblastoma Multiforme Market

9.2.5.    Spain Glioma Glioblastoma Multiforme Market

9.2.6.    Russia Glioma Glioblastoma Multiforme Market

9.2.7.    Poland Glioma Glioblastoma Multiforme Market

9.2.8.    BENELUX Glioma Glioblastoma Multiforme Market

9.2.9.    NORDIC Glioma Glioblastoma Multiforme Market

9.2.10.    Rest of Europe Glioma Glioblastoma Multiforme Market

9.3.    Europe Glioma Glioblastoma Multiforme Market, By Therapy

9.3.1.    Segment A

9.3.2.    Segment B

9.3.3.    Segment C

9.3.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

9.4.    Europe Glioma Glioblastoma Multiforme Market, By Treatment Type

9.4.1.    Segment A

9.4.2.    Segment B

9.4.3.    Segment C

9.4.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

9.5.    Europe Glioma Glioblastoma Multiforme Market, By Drug Type

9.5.1.    Segment A

9.5.2.    Segment B

9.5.3.    Segment C

9.5.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

9.6.    Europe Glioma Glioblastoma Multiforme Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Therapy

9.6.3.    By Treatment Type

9.6.4.    By Drug Type

10.    Asia Pacific Glioma Glioblastoma Multiforme Market Analysis and Forecast, 2019–2027

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Glioma Glioblastoma Multiforme Market

10.2.2.    India Glioma Glioblastoma Multiforme Market

10.2.3.    Japan Glioma Glioblastoma Multiforme Market

10.2.4.    Australia and New Zealand Glioma Glioblastoma Multiforme Market

10.2.5.    South Korea Glioma Glioblastoma Multiforme Market

10.2.6.    ASEAN Glioma Glioblastoma Multiforme Market

10.2.7.    Rest of Asia Pacific Glioma Glioblastoma Multiforme Market

10.3.    Asia Pacific Glioma Glioblastoma Multiforme Market, By Therapy

10.3.1.    Segment A

10.3.2.    Segment B

10.3.3.    Segment C

10.3.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

10.4.    Asia Pacific Glioma Glioblastoma Multiforme Market, By Treatment Type

10.4.1.    Segment A

10.4.2.    Segment B

10.4.3.    Segment C

10.4.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

10.5.    Asia Pacific Glioma Glioblastoma Multiforme Market, By Drug Type

10.5.1.    Segment A

10.5.2.    Segment B

10.5.3.    Segment C

10.5.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

10.6.    Asia Pacific Glioma Glioblastoma Multiforme Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Therapy

10.6.3.    By Treatment Type

10.6.4.    By Drug Type

11.    Middle East Glioma Glioblastoma Multiforme Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Glioma Glioblastoma Multiforme Market

11.2.2.    Israel Glioma Glioblastoma Multiforme Market

11.2.3.    Oman Glioma Glioblastoma Multiforme Market

11.2.4.    Rest of Middle East Glioma Glioblastoma Multiforme Market

11.3.    Middle East Glioma Glioblastoma Multiforme Market, By Therapy

11.3.1.    Segment A

11.3.2.    Segment B

11.3.3.    Segment C

11.3.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

11.4.    Middle East Glioma Glioblastoma Multiforme Market, By Treatment Type

11.4.1.    Segment A

11.4.2.    Segment B

11.4.3.    Segment C

11.4.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

11.5.    Middle East Glioma Glioblastoma Multiforme Market, By Drug Type

11.5.1.    Segment A

11.5.2.    Segment B

11.5.3.    Segment C

11.5.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

11.6.    Middle East Glioma Glioblastoma Multiforme Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Therapy

11.6.3.    By Treatment Type

11.6.4.    By Drug Type

12.    Africa Glioma Glioblastoma Multiforme Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Glioma Glioblastoma Multiforme Market

12.2.2.    Egypt Glioma Glioblastoma Multiforme Market

12.2.3.    North Africa Glioma Glioblastoma Multiforme Market

12.2.4.    Rest of Africa Glioma Glioblastoma Multiforme Market

12.3.    Africa Glioma Glioblastoma Multiforme Market, By Therapy

12.3.1.    Segment A

12.3.2.    Segment B

12.3.3.    Segment C

12.3.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

12.4.    Africa Glioma Glioblastoma Multiforme Market, By Treatment Type

12.4.1.    Segment A

12.4.2.    Segment B

12.4.3.    Segment C

12.4.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

12.5.    Africa Glioma Glioblastoma Multiforme Market, By Drug Type

12.5.1.    Segment A

12.5.2.    Segment B

12.5.3.    Segment C

12.5.4.    Segment D (Please Request Sample for Segmentation and Other Info.)

12.6.    Africa Glioma Glioblastoma Multiforme Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Therapy

12.6.3.    By Treatment Type

12.6.4.    By Drug Type

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    Bristol-Myers Squibb

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.     Genentech, Inc.

14.3.3.    Emcure Pharmaceuticals Limited

14.3.4.    Arbor Pharmaceuticals, LLC

14.3.5.     F. Hoffmann-La Roche AG

14.3.6.    Merck & Co., Inc.

14.3.7.     Sun Pharmaceutical Industries, Ltd.

14.3.8.     Teva Pharmaceutical Industries

14.3.9.    Sigma-Tau Pharmaceuticals, Inc.

14.3.10.    Sandoz

15.    Acronyms

Select License Type

Frequently Asked Questions

The global glioma glioblastoma multiforme market in 2020 is estimated for more than US$ 840.7 Mn and expected to reach a value of US$ 1,504.8 Mn by 2028 with a significant CAGR of 7.6%.

The studies in the cancer segment is increasingly emphasized and prioritized as a research framework to deal with complex socio-environmental problems this in turn will be used as the data extraction point for the study of the glioma glioblastoma multiforme market

The global glioma glioblastoma multiforme market is segmented on the basis of therapy, treatment type, drug type, and by region.

Bristol-Myers Squibb, Genentech, Inc., Emcure Pharmaceuticals Limited, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries, Sigma-Tau Pharmaceuticals, Inc., and Sandoz are the key participating players in the market



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK